Clinical trials: Narrow Margin
Breast Cancer
Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy
Breast cancer patients often receive systemic drugs as the initial curative treatment of their disease. The initial systemic therapy leads to a variable degree of tumor shrinkage.
- Trial name
- NCT03417622
- Testing
- Bracketing, Neoadjuvant therapy, Post-treatment volume margin resection
- Where
- Egypt
- Volunteers
- 370 people
- Sponsor
- Mansoura University
Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant concurrent chemoradiotherapy with simultaneous integrated boost following hepatectomy for intrahepatic cholangiocarcinoma…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement
- Trial name
- NCT07063888
- Testing
- Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oral Cancer
NBI in Oral Cavity Cancer
Oral cancer starts in the mucosa of the mouth and the most common site is the tongue and gingiva. One of the most important issues for the prognosis is to surgically remove all the cancer, at the sides as well as at the deep…
- Trial name
- NCT04398121
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Region Örebro County
Hepatocellular Carcinoma, Radiotherapy
Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)
RAISE is a multicenter randomized controlled trial to assess the efficacy of adjuvant radiotherapy for controlling postsurgical recurrence in HCC patients with narrow margin (≤ 1 cm) after curative resection.
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Hepatectomy
- Trial name
- RAISE (NCT03732105)
- Testing
- Surgery-radiotherapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC (NCT02309788)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to see if disease free survival and overall…
- Trial name
- NCT04891874
- Testing
- Stereotactic radiotherapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Skin Basal Cell Carcinoma
Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery
This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face.
- Trial name
- NCT02579551
- Testing
- Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Gastric Tumors
Usefulness of Near-focus With Narrow-band Imaging
Near-focus with narrow-band imaging is a novel technique to improve the quality of images of the irregular mucosal structures and microvessels of gastric neoplasms.
- Trial name
- NCT02661945
- Testing
- Near focus with narrow band imaging
- Where
- 7 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Kyunghee University Medical Center
Hepatocellular Carcinoma, Narrow Margin
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial…
- Conditions
- Hepatocellular Carcinoma, Narrow Margin, Adjuvant Stereotactic Body Radiotherapy, Hepatectomy
- Trial name
- NCT05602974
- Testing
- stereotactic body radiation therapy, regular follow-up
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Basal Cell Carcinoma
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
The purpose of this study is to determine the narrowest excision margin for head and neck Basal Cell Carcinoma (BCC) tumors satisfying the National Comprehensive Cancer Network® (NCCN) low-risk for recurrence clinical and…
- Trial name
- NCT01903239
- Testing
- Low-Risk BCC Excisional Margins
- Where
- 2 sites in United States
- Volunteers
- 179 people
- Sponsor
- Thomas Jefferson University
HCC - Hepatocellular Carcinoma
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Postoperative recurrence remains a major limitation to long-term survival in hepatocellular carcinoma (HCC). In addition, a narrow surgical margin is widely regarded as a risk factor for recurrence.
- Trial name
- NCT07518706
- Testing
- Tislelizumab, Lenvatinib
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Narrow Margin
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant simultaneouslyintegrated boost radiotherapy following narrow-margin(<1cm) hepatectomy in patients with HCC.
- Conditions
- Hepatocellular Carcinoma, Narrow Margin, Radiotherapy
- Trial name
- NCT06205472
- Testing
- Adjuvant SIB radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
NBI for Identifying Resection Margin Status in Gastric Cancer
As the proportion of early gastric cancer has been steadily increased in Korea, so has function-preserving surgery. The function preserving surgery is characterized by the minimized extent of gastrectomy, so this implies that…
- Trial name
- NCT02926716
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Ajou University School of Medicine
Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx
Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers
The aim of this study is to prospectively determine if the use of NBI endoscopy modifies the superficial extension of these tumors.
- Conditions
- Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx
- Trial name
- NCT02035735
- Testing
- WL and NBI
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Toulouse
Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma.
- Trial name
- NCT06673095
- Testing
- Biospecimen Collection, Excision, Survey Administration
- Where
- 5 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- OHSU Knight Cancer Institute
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion
Hepatocellular carcinoma is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC:BCLC-A (NCT02678806)
- Testing
- Postoperative radiotherapy, Postoperative TACE
- Where
- China
- Volunteers
- 620 people
- Sponsor
- Guangxi Medical University